News | November 01, 2024
AbbVie to acquire Aliada Therapeutics
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Strengthening focus in Alzheimer's disease and neuroscience pipeline
A first-in-class muscarinic agonist for the treatment of schizophrenia in adults
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
WINLEVI works differently from any other topical acne treatment
Subscribe To Our Newsletter & Stay Updated
